NTHI NEONC TECHNOLOGIES HOLDINGS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1979414 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY12.0%
TTM EPS YoY25.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-642.8%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets241.6%
Debt / equity—
Current ratio0.38x
Interest coverage-15.69x
Cash quality & payout
Operating cash flow / net income0.48x
Accruals ratio-337.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | — | $0 | $0 | $0 | $39,990 | $20,000 |
| R&D expense | $1.31M | $2.65M | $1.29M | $1.25M | $715,038 | $677,332 | $998,222 | $1.08M |
| SG&A expense | $636,620 | $895,559 | $488,709 | $2.08M | $902,985 | $984,262 | $849,485 | $705,737 |
| Operating income | -$5.83M | -$14.07M | -$7.06M | -$13.70M | -$6.93M | -$5.71M | -$31.90M | -$2.11M |
| Interest expense | $97,508 | $234,370 | $982,624 | $1.28M | $869,815 | $48,750 | $308,922 | -$2,401 |
| Net income | -$4.44M | -$14.24M | -$8.82M | -$15.52M | -$8.62M | -$5.68M | -$32.33M | -$2.25M |
| EPS (basic) | -0.28 | -0.58 | -0.38 | — | -0.45 | -0.30 | -1.78 | — |
| EPS (diluted) | -0.28 | -0.58 | -0.38 | — | -0.45 | -0.30 | -1.78 | — |
| Weighted avg. shares (diluted) | 25.78M | 24.66M | 23.29M | — | 19.21M | 19.03M | 18.14M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $6.17M | $1.97M | $138,601 | $58,729 | $1.51M | $125,039 | $5.44M | $64,893 |
| Current assets | $8.46M | $4.19M | $2.10M | $1.39M | $2.96M | $1.65M | $7.36M | $2.20M |
| Intangibles | $474,537 | $481,481 | $488,426 | $500,000 | — | — | — | — |
| Total assets | $9.30M | $5.23M | $3.33M | $2.82M | $4.08M | $2.99M | $8.44M | $3.42M |
| Current liabilities | $22.24M | $23.51M | $16.29M | $20.04M | $15.59M | $14.48M | $18.07M | $8.92M |
| Total liabilities | $22.48M | $23.76M | $16.56M | $20.33M | $15.90M | $14.80M | $18.07M | $8.92M |
| Shareholders' equity | -$13.17M | -$18.53M | -$13.23M | -$17.51M | -$11.81M | -$11.82M | -$9.62M | -$5.50M |
| Shares outstanding | 28.85M | 25.93M | 24.83M | 21.99M | 19.47M | 19.03M | 19.03M | 18.09M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.09M | -$4.77M | -$6.99M | -$3.59M | -$5.81M | -$5.31M | -$5.65M | -$954,404 |
| Financing cash flow | $9.28M | $6.60M | $7.07M | $2.64M | $7.20M | $0 | $11.02M | -$315,330 |
| Stock-based compensation | $267,565 | $5.65M | $2.73M | $9.59M | $5.04M | $3.53M | $17.40M | — |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.